GenFleet Therapeutics Joins Hang Seng Index SeriesGenFleet Therapeutics (Shanghai) Inc. said it will be included in the Hang Seng Index Series from March 9, 2026, including the Hang Seng Composite Index, the Hang Seng Stock Connect Hong Kong Index, and the Hang Seng Innovative Drug Index
Reuters03-09
GenFleet <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Joins <a href="https://laohu8.com/S/HSNGF">Hang Seng</a> Index Series GenFleet Therapeutics (Shanghai) Inc. said it will be included in the <a href="https://laohu8.com/S/HSNGY">Hang Seng</a> Index Series from March 9, 2026, including the Hang Seng Composite Index, the Hang Seng Stock Connect Hong Kong Index, and the Hang Seng Innovative Drug Index
GenFleet Therapeutics (Shanghai) Inc. will be added as a constituent to the Hang Seng Index Series, effective March 9, 2026, including the Hang Seng Composite Index, the Hang Seng Stock Connect Hong Kong Index, and the Hang Seng Innovative Drug Index. The company said the change follows its inclusion in the eligible shares list of the Stock Connect Program.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genfleet Therapeutics (Shanghai) Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260309-12044989), on March 09, 2026, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments